Rejuvenate Bio 與動物健康公司建立戰略合作夥伴關係
鑽石於2023年投資Rejuvenate Bio Inc.，Rejuvenate Bio 是一家基因治療公司，利用哈佛Wyss研究所（Harvard Wyss Institute）開發的突破性技術來治療慢性疾病。本篇文章於2024年02月發表於Longevity Technology，宣佈與一家「全球動物保健公司」建立策略合作夥伴關係，以推進在治療犬骨關節炎的基因療法的開發和商業化。
Rejuvenate Bio makes progress on osteoarthritis gene therapy for dogs
Author: Danny Sullivan | Published on: February 19, 2024 | Last updated: February 19, 2024
Longevity biotech company Rejuvenate Bio has revealed a strategic partnership to advance the development and commercialization of its gene therapy designed to address canine osteoarthritis. The collaboration with an unnamed “global animal health company” aims to combat the debilitating chronic disease that affects many dogs’ mobility and wellbeing.
Rejuvenate Bio’s gene therapy, developed based on research conducted in the lab of Professor George Church at the Wyss Institute at Harvard Medical School, is working on a one-dose injection solution for addressing osteoarthritis. The potentially disease-modifying therapy targets the underlying causes of the disease, and aims to provide long-term relief, ultimately improving joint health and enhancing the quality of life for affected animals.
San Diego-based Rejuvenate Bio, which specializes in developing gene therapies for chronic age-related diseases in both humans and animals, claims that osteoarthritis affects over 40% of dogs but is often undiagnosed and undertreated, leading to a decline in overall health.
“The ramifications of OA extend beyond physical discomfort, as OA is a leading cause of euthanasia in dogs,” said Dan Oliver, CEO of Rejuvenate Bio. “This partnership with a leading animal health company validates our technology and approach of utilizing gene therapy to treat chronic age-related diseases and ensures that this therapy will reach the dogs that need it.”
This latest partnership follows Rejuvenate Bio’s partnership with Phibro Animal Health to develop a gene therapy for mitral valve disease in dogs. The company secured a $10 million Series A funding round in 2021.